caa a22 4500 475803752 CHVBK 20180406123744.0 cr unu---uuuuu 170329e20001101xx s 000 0 eng 10.1007/s002680010217 doi (NATIONALLICENCE)springer-10.1007/s002680010217 Is the New Classification of Neuroendocrine Pancreatic Tumors of Clinical Help? [Elektronische Daten] [Martin Schindl, Klaus Kaczirek, Klaus Kaserer, Bruno Niederle] A new concept of classifying neuroendocrine pancreatic tumors based on clinicopathologic patterns was summarized recently. To evaluate the clinical reliability and prognostic specificity of this classification system, 100 neuroendocrine pancreatic tumors were retrospectively categorized as "benign,”"uncertain,” and "malignant” based on tumor risk factors (size, local invasion and angioinvasion, cell atypia, metastases) and were followed for disease recurrence and progression. Altogether, 71 functioning tumors (insulinoma, gastrinoma, glucagonoma, enterochromaffin-like (ECL)oma, somatostatinoma) and 29 nonfunctioning neuroendocrine pancreatic tumors (NETs) were studied. NETs had an increased risk of malignancy (p < 0.05). Tumor size, gross invasion, and metastases correlated significantly with tumor behavior and allowed us to distinguish between "benign” and "malignant” tumors. About 89% of the tumors ≤ 20 mm were "benign,” whereas 71% > 20 mm were "malignant” (p < 0.05). In patients with "benign” and "uncertain” neuroendocrine pancreatic tumors, neither recurrence nor progression of disease was seen. About 41% of the patients with "malignant” tumors died of the disease. The 5-year estimated cumulative survival of those with "benign” and "uncertain” tumors was 100% and 52 ± 10% for those with "malignant” tumors (p < 0.05). Histomorphologic details classifying the behavior of an "uncertain” tumor are known only after initial treatment and definitive histopathologic investigation. Thus this information is of limited clinical help for treatment strategies. Société Internationale de Chirurgie, 2000 Schindl Martin Department of Surgery, Division of General Surgery, Section of Endocrine Surgery, University of Vienna Medical School, Währinger Gürtel 18-20, A 1090 Vienna, Austria, AT aut Kaczirek Klaus Department of Surgery, Division of General Surgery, Section of Endocrine Surgery, University of Vienna Medical School, Währinger Gürtel 18-20, A 1090 Vienna, Austria, AT aut Kaserer Klaus Institute of Clinical Pathology, University of Vienna Medical School, Währinger Gürtel 18-20, A 1090 Vienna, Austria, AT aut Niederle Bruno Department of Surgery, Division of General Surgery, Section of Endocrine Surgery, University of Vienna Medical School, Währinger Gürtel 18-20, A 1090 Vienna, Austria, AT aut World Journal of Surgery Springer-Verlag 24/11(2000-11-01), 1312-1318 0364-2313 24:11<1312 2000 24 268 https://doi.org/10.1007/s002680010217 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002680010217 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Schindl Martin Department of Surgery, Division of General Surgery, Section of Endocrine Surgery, University of Vienna Medical School, Währinger Gürtel 18-20, A 1090 Vienna, Austria, AT aut NATIONALLICENCE 700 1- Kaczirek Klaus Department of Surgery, Division of General Surgery, Section of Endocrine Surgery, University of Vienna Medical School, Währinger Gürtel 18-20, A 1090 Vienna, Austria, AT aut NATIONALLICENCE 700 1- Kaserer Klaus Institute of Clinical Pathology, University of Vienna Medical School, Währinger Gürtel 18-20, A 1090 Vienna, Austria, AT aut NATIONALLICENCE 700 1- Niederle Bruno Department of Surgery, Division of General Surgery, Section of Endocrine Surgery, University of Vienna Medical School, Währinger Gürtel 18-20, A 1090 Vienna, Austria, AT aut NATIONALLICENCE 773 0- World Journal of Surgery Springer-Verlag 24/11(2000-11-01), 1312-1318 0364-2313 24:11<1312 2000 24 268 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer